Search

Your search keyword '"Van Elssen, Catharina"' showing total 14 results
Start Over Author "Van Elssen, Catharina" Publication Year Range Last 3 years
14 results on '"Van Elssen, Catharina"'

1. Low Levels of Serum and Intracellular Vitamin C in Hospitalized COVID-19 Patients

Author

Boerenkamp, Lara S., primary, Gijsbers, Birgit L. M. G., additional, Ververs, Erik-Jan, additional, Pijpers, Eva M. S., additional, Spaetgens, Bart, additional, de Coninck, Aniek, additional, Germeraad, Wilfred T. V., additional, Wodzig, Will K. W. H., additional, Wieten, Lotte, additional, van Gorkom, Gwendolyn N. Y., additional, and van Elssen, Catharina H. M. J., additional

Published
2023
Full Text
View/download PDF

2. P1387: TREATMENT WITH A LEUKEMIA-DERIVED DENDRITIC CELL VACCINE INDUCES INNATE AND ADAPTIVE IMMUNE RESPONSE CORRELATING WITH CLINICAL RESPONSE IN AML PATIENTS IN CR1 WITH MEASURABLE RESIDUAL DISEASE

Author

van Zeeburg, Hester, primary, Kaur Singh, Satwinder, additional, Wagner-Drouet, Eva, additional, Platzbecker, Uwe, additional, Holderried, Tobias, additional, VAN Elssen, Catharina, additional, Giagounidis, Aristoteles, additional, Tore Gjertsen, Bjorn, additional, van de Loosdrecht, Arjan, additional, and Rovers, Jeroen, additional

Published
2023
Full Text
View/download PDF

3. Use of an Allogeneic Leukemia-Derived Dendritic Cell Vaccine in MRD+ AML-Patients Results in MRD Conversion, Improved Relapse-Free Survival and Vaccine Induced Immune Responses to Tumor Antigens

Author

Van de Loosdrecht, Arjan A., primary, Cloos, Jacqueline, additional, Wagner-Drouet, Eva-Maria, additional, Platzbecker, Uwe, additional, Holderried, Tobias A.W., additional, van Elssen, Catharina, additional, Giagounidis, Aristoteles, additional, Lehmann, Sören, additional, van Zeeburg, Hester J.T., additional, Rovers, Jeroen, additional, and Gjertsen, Bjorn T., additional

Published
2022
Full Text
View/download PDF

4. Induction of a Systemic Immune Response during Use of an Allogenic Leukemia-Derived Dendritic Cell Vaccine in MRD+ AML Patients Correlates with Clinical Response and MRD Conversion

Author

Van de Loosdrecht, Arjan A., primary, Cloos, Jacqueline, additional, Wagner-Drouet, Eva-Maria, additional, Platzbecker, Uwe, additional, Holderried, Tobias A.W., additional, van Elssen, Catharina, additional, Giagounidis, Aristoteles, additional, Welters, Marij J.P., additional, van der Burg, Sjoerd H., additional, van Zeeburg, Hester J.T., additional, Rovers, Jeroen, additional, and Gjertsen, Bjorn T., additional

Published
2022
Full Text
View/download PDF

5. No Effect of Vitamin C Administration on Neutrophil Recovery in Autologous Stem Cell Transplantation for Myeloma or Lymphoma: A Blinded, Randomized Placebo-Controlled Trial

Author

van Gorkom, Gwendolyn N. Y., primary, Boerenkamp, Lara S., additional, Gijsbers, Birgit L. M. G., additional, van Ojik, Heidi H., additional, Wodzig, Will K. W. H., additional, Wieten, Lotte, additional, Van Elssen, Catharina H. M. J., additional, and Bos, Gerard M. J., additional

Published
2022
Full Text
View/download PDF

6. Concordance in measurable residual disease result after first and second induction cycle in acute myeloid leukemia: An outcome- and cost-analysis

Author

Tettero, Jesse M., primary, Al-Badri, Waleed K. W., additional, Ngai, Lok Lam, additional, Bachas, Costa, additional, Breems, Dimitri A., additional, van Elssen, Catharina H. M. J., additional, Fischer, Thomas, additional, Gjertsen, Bjorn T., additional, van Gorkom, Gwendolyn N. Y., additional, Gradowska, Patrycja, additional, Greuter, Marjolein J. E., additional, Griskevicius, Laimonas, additional, Juliusson, Gunnar, additional, Maertens, Johan, additional, Manz, Markus G., additional, Pabst, Thomas, additional, Passweg, Jakob, additional, Porkka, Kimmo, additional, Löwenberg, Bob, additional, Ossenkoppele, Gert J., additional, Janssen, Jeroen J. W. M., additional, and Cloos, Jacqueline, additional

Published
2022
Full Text
View/download PDF

7. Increased CD8 T‐cell immunity after COVID‐19 vaccination in lymphoid malignancy patients lacking adequate humoral response: An immune compensation mechanism?

Author

Boerenkamp, Lara S., primary, Pothast, Cilia R., additional, Dijkland, Romy C., additional, van Dijk, Kayleigh, additional, van Gorkom, Gwendolyn N. Y., additional, van Loo, Inge H. M., additional, Wieten, Lotte, additional, Halkes, Constantijn J. M., additional, Heemskerk, Mirjam H. M., additional, and Van Elssen, Catharina H. M. J., additional

Published
2022
Full Text
View/download PDF

8. MM-349 Talquetamab (Tal), a GPRC5D×CD3 Bispecific Antibody (BsAb), in Combination With Pomalidomide (Pom) in Patients With Relapsed/Refractory Multiple Myeloma (RRMM): Efficacy and Safety Results From the Phase 1b MonumenTAL-2 Study

Author

Searle, Emma, Quach, Hang, Biran, Noa, Perrot, Aurore, Berdeja, Jesus G, Dorritie, Kathleen, Van Elssen, Catharina, Touzeau, Cyrille, Anguille, Sébastien, Vishwamitra, Deeksha, Nguyen, Ashley, Ghosh, Debopriya, Shearin, Elizabeth, E, Gary, Renaud, Thomas, and Matous, Jeffrey

Published
2024
Full Text
View/download PDF

9. Talquetamab (Tal), a GPRC5D×CD3 Bispecific Antibody (BsAb), in Combination With Pomalidomide (Pom) in Patients With Relapsed/Refractory Multiple Myeloma (RRMM): Efficacy and Safety Results From the Phase 1b MonumenTAL-2 Study

Author

Searle, Emma, Quach, Hang, Biran, Noa, Perrot, Aurore, Berdeja, Jesus G, Dorritie, Kathleen, Van Elssen, Catharina, Touzeau, Cyrille, Anguille, Sébastien, Vishwamitra, Deeksha, Nguyen, Ashley, Ghosh, Debopriya, Shearin, Elizabeth, Mason, Gary E, Renaud, Thomas, and Matous, Jeffrey

Published
2024
Full Text
View/download PDF

12. The impact of donor type on resource utilisation and costs in allogeneic haematopoietic stem cell transplantation in the Netherlands.

Author

van Gorkom, Gwendolyn, Van Elssen, Catharina, Janssen, Ian, Groothuis, Siebren, Evers, Silvia, and Bos, Gerard

Subjects
*HEMATOPOIETIC stem cell transplantation
Abstract

Background: Allogeneic haematopoietic stem cell transplantation (HSCT) is increasingly used, but this treatment is complex and costly. As clinical outcomes of HSCT with matched unrelated donor (MUD) and haploidentical donors are similar, costs could influence donor choice. Method: We retrospectively compared resource utilisation and costs of HSCT using the three different donor types (matched related donor (MRD) (n = 32), haploidentical related (n = 30) and MUD (n = 60)) within the first year after transplantation. Costs were analysed through a bottom‐up method. Non‐parametric bootstrapping was applied to test for statistical differences in costs. Subgroup analyses were performed to identify predictors for costs. Results: Cost pre‐transplant for search and acquisition of the graft were significantly higher in MUD HSCT (€35 222) versus MRD and haploidentical HSCT (€15 356 and €16 097 respectively). The costs of haploidentical HSCT were the highest in the transplant phase. Main cost factors were inpatient days and medication. Overall, the costs for haploidentical and MUD HSCT were similar (€115 724 for MUD, €113 312 for haploidentical). Conclusion: Our study suggests no difference in total transplantation costs between allogeneic HSCT using a MUD or a haploidentical donor. Since clinical outcomes seem similar as well, the choice of donor type might be based on availability, speed and logistics. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

13. Vaccination Using an Allogeneic Leukemia-Derived Dendritic Cell Vaccine, Maintains and Improves Frequencies of Circulating Antigen Presenting Dendritic Cells Correlating with Relapse Free and Overall Survival in AML Patients

Author

Van Zeeburg, Hester, Wagner Drouet, Eva, Platzbecker, Uwe, Holderried, Tobias A.W., Van Elssen, Catharina, Giagounidis, Aristoteles, Lehmann, Soren, Rovers, Jeroen, Gjertsen, Bjorn T., and van de Loosdrecht, Arjan A.

Abstract

Background.Active immunotherapy relies on the patient's immune system for induction of an effective immune response. Not only the frequency, number and exhaustion or activation status of CD8 T cells is important for an efficacious tumor cell lysis, but the quality, number and distribution of different antigen presenting cells is of equal importance. Vididencel is an allogeneic leukemia-derived dendritic cell vaccine used in AML patients in first complete remission (CR1/CRi), but with MRD positivity, to mount an immune response through intradermal vaccination (ADVANCE-II, Clintrials.gov: NCT03697707). Intradermal vaccination is known to induce a specific immune response, by recruitment of skin and blood derived dendritic cells, which process antigen and present them to the immune system (Zuo et al., 2021). In this study circulating dendritic cells and monocytes have been investigated before and during vaccination to investigate the effect of vididencel treatment on the composition of antigen presenting cells in relation to clinical responses.

Published
2023
Full Text
View/download PDF

14. Induction of Cellular and Humoral Immune Responses Is Associated with Durable Remissions in MRD+ AML-Patients after Maintenance Treatment with an Allogeneic Leukemia-Derived Dendritic Cell Vaccine

Author

van de Loosdrecht, Arjan A., Wagner Drouet, Eva, Platzbecker, Uwe, Holderried, Tobias A.W., Van Elssen, Catharina, Giagounidis, Aristoteles, Lehmann, Soren, Van Zeeburg, Hester, Rovers, Jeroen, and Gjertsen, Bjorn T.

Abstract

Background.Maintaining remission in AML after intensive chemotherapy continues to be a challenge, specifically in patients with measurable residual disease (MRD+). Immunotherapy could be an effective way to induce durable disease control for patients in remission. This phase 2 study used an allogenic leukemia-derived dendritic cell vaccine to induce an effective anti-leukemic response to control or eradicated MRD, leading to durable disease control. (ADVANCE-II, Clintrials.gov: NCT03697707).

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results